Iridocorneal endothelial syndrome (ICES) is a group of eye diseases characterized by pathology of the endothelial layer of the cornea and iris. This condition leads to various disturbances, including corneal edema, increased intraocular pressure, and changes in the anatomy of the anterior segment of the eye. ICES can manifest itself in three main subtypes: Nader syndrome, Stewart syndrome, and Peganov syndrome. These diseases have similar clinical manifestations, but require an individualized approach to diagnosis and treatment. Although the main manifestation of ICES is corneal neuropathy, the pathology also affects deeper structures of the eye, and the risk of progressive deterioration of vision is high.
History of the disease and interesting historical facts
Historically, ICES was first described in the 1970s, when doctors began to associate the symptoms with changes in the endothelial cell population and its functions. In 1975, doctors J. Hampton and K. Worins recorded the described condition, and since then its study has become more active. One of the interesting facts is that for a long time, the disease was not associated with genetic factors, although already in the 1980s, research began to establish a connection between genetic abnormalities and the development of ICES.
Epidemiology
This pathology is considered rare, but according to statistics, its prevalence varies from 0.5 to 5% among the population. ICES is more common in women than in men, with the peak age of onset between 30 and 60 years. According to a study conducted in 2019, in a population with certain forms of glaucoma, the prevalence of ICES increases almost twofold.
Genetic predisposition to this disease
Research suggests that certain mutations in genes associated with the development of ICES may be inherited. Among the genes implicated, the most frequently mentioned are *COL4A1*, *KDR*, and *RBP4*. Mutations in these genes may lead to disruptions in the structural integrity of the cornea and iris, which in turn causes adverse changes in the endothelial cell population. Understanding the genetic basis of the disease may open up new horizons in diagnostics and targeted therapy.
Risk factors for the development of this disease
Risk factors contributing to the development of ICE are multifaceted and may include both physical and chemical exposures. The main risk factors include:
- Eye injuries (mechanical or chemical) – especially penetrating injuries.
- Heredity – the presence of relatives with similar diseases.
- Immunosuppression – caused by treatment or concomitant diseases.
- Contact with toxic substances – for example, those found in work areas at enterprises with high chemical loads.
Diagnosis of this disease
Diagnosis of ICES is a complex task requiring a comprehensive approach. The main symptoms include:
- Corneal edema, manifested by deterioration of vision.
- Increased intraocular pressure.
- Discomfort, burning or photophobia.
- Changes in the color of the iris.
Laboratory tests may include tear fluid analysis for inflammatory markers. Radiological methods such as ultrasound and optical coherence tomography (OCT) may be needed to study the tissue structure in detail. Differential diagnosis is important to exclude other pathologies such as glaucoma or keratoconus.
Treatment
Treatment of ICES requires an individual approach, which depends on the severity of the disease and the degree of changes. The main areas of treatment are:
- General treatment: inclusion of vitamins to support metabolic processes in the cornea.
- Pharmacological treatment: use of drugs to control intraocular pressure and reduce corneal edema.
- Surgical treatment: may include corneal transplantation in cases of advanced disease.
- Other treatments include using contact lenses to correct vision problems due to corneal edema.
List of drugs used to treat this disease
The main drugs used to treat ICES include:
- Procaine and alpha-adrenergic agonists to reduce intraocular pressure.
- Nonsteroidal anti-inflammatory drugs to reduce inflammation.
- Topical corticosteroids to control swelling.
- An agent for slowing the progression of corneal pathology.
Disease monitoring
Monitoring of ICE includes regular follow-up examinations by an ophthalmologist, which are performed at least once every few months. The prognosis of the disease depends on many factors, including the degree of damage to the cornea and the time of treatment. Complications such as permanent decrease in visual acuity and secondary glaucoma may develop.
Age-related features of the disease
In the age group up to 30 years, ICE is rare and is more often associated with a genetic predisposition. At a more mature age (after 30 years), the manifestations of the disease may be more pronounced, and the risk of complications increases significantly. In older people, the disease may proceed in a more severe form, which is associated with a combination of all risk factors exposed to the eye.
Questions and Answers
- What is iridocorneal endothelial syndrome? This is a group of diseases characterized by changes in the endothelial layer of the cornea, which leads to swelling and other disturbances in the anterior parts of the eye.
- What are the main symptoms of ICES? The main symptoms include swelling of the cornea, increased intraocular pressure, discomfort in the eye, and changes in the color of the iris.
- How is this disease diagnosed? Diagnostics includes clinical examinations, laboratory tests, ultrasound and optical coherence tomography.
- What is the treatment for ICES? Treatment can be conservative (pharmacological) or surgical, depending on the stage and severity of the disease.
- What is the prognosis for patients with ICES? The prognosis depends on early diagnosis and time of treatment; complications may occur if adequate treatment is not given.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov advises paying attention to eye health and consulting a doctor at the slightest changes in vision. Regular ophthalmological examinations help identify potential problems at early stages, which significantly improves the prognosis and treatment outcome. It is also important to monitor eye moisture and protect them from injury, especially when working in conditions associated with chemical exposure.
